Syneos Health, Inc.

Good morning, everyone. With me on the call today are Alistair McDonald, Jason Meggs, Michelle Keefe, and Michael Brooks. In addition to the press release, a slide presentation corresponding to our prepared remarks is available on our website at investor.cineoshealth.com. Remarks that we make about future expectations, growth, trends, anticipated financial results, and our expectations regarding the COVID-19 pandemic and the war in Ukraine constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, and we disclaim any obligation to update them. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors. These factors are discussed in the risk factors section of our Form 10-K for the year end of December 31, 2021, and our other SEC filings. During this call, we will discuss certain non-GAAP financial measures, which exclude the effects of events and transactions we consider to be outside of our core operations. These non-GAAP measures should be considered a supplement to, and not a replacement for, measures prepared in accordance with GAAP. For reconciliation of non-GAAP financial measures with the most directly comparable GAAP measures, please refer to the appendix of our presentation. I would now like to turn the call over to Alistair MacDonald. Alistair?

Thanks, Ronnie. Good morning, everyone, and thank you for joining us today. Before we begin discussing our first quarter results, I wanted to share some important news that we announced with our earnings today. After spending 20 years with Cineos Health, I have decided to retire from the company. I am very proud that Michelle Keefe, our current president of medical affairs and commercial solutions, will be assuming the role of CEO and board member, leading Cineos Health moving forwards. Michelle was the unanimous choice following an extensive search process conducted by our board, and having worked alongside her since 2017, I am confident that she is the right person for the job. With the succession plan now in place, I will be stepping down a CEO member of the board effective today. However, I will continue as an advisor for the next few months in order to ensure a smooth transition. During my 20 years with the company, we have made incredible progress transforming Sineos Health from a small, traditional contract research organization into a fully integrated biopharmaceutical solutions provider. Today, with our integrated solutions and compelling market position firmly established, we are better positioned for long-term growth and value creation than ever before. The board and I have full confidence that now is the right time for a new leader to take the company into its next chapter. During her 30-year career in the life sciences industry, Michelle has established herself as an accomplished executive with an impressive track record of execution, innovation, and customer success. Since joining Sineos Health in 2017, her leadership has driven the ongoing transformation of our commercial business, where she has built a world-class management team and a strong business development organization that has diversified and strengthened our commercial portfolio. The successes across the product development continuum include launching innovative services like Kinetic, enhancing our unique product development approach by building integrated services such as full-service commercial and medical affairs, while collaborating to drive growth in our unique Cineos One offering. Under Michelle's leadership, the Commercial Solutions Organization is experiencing its second straight year of double-digit growth. In just four years, she has become an invaluable member of our senior team, trusted and respected by customers and employees alike. She brings the expertise necessary to take the company into the next era as a data and insights-driven organization, and I know she is the right leader to drive Cineos Health's continued momentum into the future. Michelle joins us here today, and before we turn back to our first quarter results, I'll hand it over to her for some brief comments. Michelle? Michelle?

Thanks, Alistair. To start, I want to thank Alistair for his partnership and guidance over these past four and a half years. He has been an excellent leader and mentor, and it is thanks to his vision and passion that Cineos Health stands where it does today, with an industry-leading end-to-end solutions portfolio, purpose-built to help our customers shorten the distance from lab to life. As I take on this new role, my top priority will be to push our capabilities to the next level and accelerate our evolution toward becoming a more intelligent enterprise and impactful healthcare leader. I see a tremendous market opportunity to provide customers with a more meaningful, insight-driven conversation that is tailored to the needs of our patients, sites, and healthcare providers. As we head into our next phase of growth, I look forward to building on our innovative, data-driven approach through disciplined investments in our technology and our people that will position us and our customers for the future. I am also pleased to share that in connection with this transition, I have appointed Michael Brooks, our current Chief Development Officer and Global Head of Clinical Development Solutions, to the newly created role of Chief Operating Officer. As COO, Michael will be responsible for seamlessly connecting clinical development, medical affairs, and commercial solutions with a focus on creating greater customer success through integrated solutions and technology-driven insights. He brings more than 25 years of clinical development and commercialization experience to this role and I look forward to benefiting from his insights as we work together to deliver on the company's strategic goals. I am energized by the opportunities ahead for Cineos Health and eager to get started. Over the coming weeks, I'll be listening to and learning from our employees, customers, partners, and investors to hear as many perspectives on our business as possible. I look forward to providing you all an update on our next earnings call. With that, I'll turn the call back to Alistair to discuss the first quarter.